VEA
AXSM icon

Virtus ETF Advisers’s Axsome Therapeutics AXSM Stock Holding History

Virtus ETF Advisers’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,705
Closed -$313K – 461
2024
Q4 		$313K Sell
3,705
-837
-18% -$77K 0.13% 242
2024
Q3 		$408K Hold
4,542
– – 0.19% 199
2024
Q2 		$366K Sell
4,542
-658
-13% -$48.7K 0.18% 188
2024
Q1 		$415K Buy
5,200
+748
+17% +$62.8K 0.22% 190
2023
Q4 		$354K Buy
4,452
+690
+18% +$46.1K 0.22% 184
2023
Q3 		$263K Sell
3,762
-485
-11% -$36.3K 0.16% 218
2023
Q2 		$305K Buy
4,247
+387
+10% +$28.5K 0.18% 203
2023
Q1 		$238K Buy
3,860
+65
+2% +$4.27K 0.13% 292
2022
Q4 		$293K Sell
3,795
-6,618
-64% -$396K 0.15% 279
2022
Q3 		$465K Buy
10,413
+154
+2% +$7.7K 0.19% 218
2022
Q2 		$393K Buy
10,259
+5,206
+103% +$165K 0.15% 255
2022
Q1 		$209K Sell
5,053
-297
-6% -$9.21K 0.09% 195
2021
Q4 		$202K Buy
5,350
+2,204
+70% +$81.1K 0.08% 203
2021
Q3 		$104K Sell
3,146
-167
-5% -$6.51K 0.05% 379
2021
Q2 		$223K Sell
3,313
-445
-12% -$26.7K 0.09% 265
2021
Q1 		$213K Buy
3,758
+68
+2% +$4.78K 0.09% 316
2020
Q4 		$301K Sell
3,690
-579
-14% -$43.3K 0.12% 208
2020
Q3 		$304K Sell
4,269
-570
-12% -$44.4K 0.16% 217
2020
Q2 		$398K Sell
4,839
-2,849
-37% -$219K 0.19% 195
2020
Q1 		$452K Sell
7,688
-1,113
-13% -$90.7K 0.19% 181
2019
Q4 		$910K Sell
8,801
-2,275
-21% -$91.9K 0.15% 151
2019
Q3 		$224K Sell
11,076
-616
-5% -$15.8K 0.05% 227
2019
Q2 		$301K Buy
+11,692
New +$234K 0.06% 210

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Virtus ETF Advisers's AXSM Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Axsome Therapeutics (AXSM) in Q1 2025, closing a stake of 3,705 shares — an estimated $313K sold.

Virtus ETF Advisers first reported a position in AXSM in Q2 2019 and held it in 23 quarters. The position peaked at $910K in Q4 2019. 353 funds tracked by Wall St. Rank hold AXSM as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Axsome Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 3,705 Axsome Therapeutics shares in Q1 2025, an estimated $313K.
  • Virtus ETF Advisers first reported a position in Axsome Therapeutics in Q2 2019 and held it in 23 quarters.
  • Virtus ETF Advisers's Axsome Therapeutics position peaked at $910K in Q4 2019.
  • 353 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.